• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

15.83 +0.12 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 699,554
Open 15.69
Bid (Size) 15.47 (600)
Ask (Size) 16.70 (100)
Prev. Close 15.71
Today's Range 15.43 - 15.95
52wk Range 2.210 - 18.31
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy ↗
December 13, 2025
PHAT stock aligns with the Minervini growth strategy, showing a strong technical uptrend and explosive 460% revenue growth, making it a high-potential momentum candidate. 
Via Chartmill
News headline image
High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) ↗
November 14, 2025
Discover a powerful stock-picking strategy combining Minervini's Trend Template with High Growth Momentum to find high-potential stocks like PHAT. 
Via Chartmill

Performance

YTD
+0.8%
+0.8%
1 Month
+6.2%
+6.2%
3 Month
+36.3%
+36.3%
6 Month
+82.8%
+82.8%
1 Year
+108.0%
+108.0%

More News

Read More
News headline image
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
November 04, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
November 03, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
October 30, 2025
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
August 07, 2025
Via Benzinga
News headline image
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance ↗
October 30, 2025
Via Chartmill
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
October 30, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
October 25, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
October 23, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
October 20, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
October 06, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
October 01, 2025
Via Benzinga
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
August 25, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
August 20, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q2 Revenue Jumps 441% ↗
August 07, 2025
Via The Motley Fool
News headline image
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket ↗
August 07, 2025
Via Chartmill
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
August 07, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
July 28, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 23, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
June 23, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
June 16, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Unusual Machines, Celldex Therapeutics, RH And Other Big Stocks Moving Higher On Friday ↗
June 13, 2025
Via Benzinga
News headline image
Phathom Pharmaceuticals Stock Doubles After FDA Grants Full 10-Year Exclusivity For Voquezna ↗
June 06, 2025
Via Benzinga
News headline image
Which stocks are moving on Friday? ↗
June 06, 2025
Via Chartmill

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 15.83
When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 01/05/26 04:00 PM ET
What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 690.41M
How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
Phathom Pharmaceuticals, Inc. - Common Stock has 690M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap